Jefferies Reiterates Buy Rating on Boston Scientific
Jefferies maintains its positive outlook on Boston Scientific with a $67 price target, a 51.48% upside from the current price.
Key Points
- Jefferies reaffirmed its buy rating for Boston Scientific Corporation (NYSE:BSX) with a price target of $67 on June 24, 2026.
- Jefferies's $67 price target implies 51.48% upside from Boston Scientific Corporation's ($BSX) current $44.23 share price.
- Shares of Boston Scientific traded near $44.62 on Wednesday, with the company having a market cap of approximately $65.89 billion.
- Recent insider activity includes several purchases in May, with analysts maintaining a strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jefferies has reiterated its buy rating for Boston Scientific Corporation (NYSE:BSX), setting a price target of $67. This reaffirmation came on June 24, 2026, as analyst Matthew Taylor continues to see potential in the medical device company.
Jefferies vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Boston Scientific Corporation Stock Down 5.6%
Shares of Boston Scientific traded near $44.62 on Wednesday. The company, which has a market capitalization of about $65.89 billion, operates in the healthcare sector, specifically in medical devices. It boasts a P/E ratio of 18.5 and a forward P/E of 11.9, reflecting its earnings potential. The stock's 52-week range is between $44.05 and $109.50, with a 50-day moving average of $54.92 and a 200-day moving average of $81.20. Boston Scientific's current ratio stands at 1.9, with a quick ratio of 0.98 and a debt-to-equity ratio of 42.25.
$BSX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Boston Scientific reported revenues of $20.61 billion, reflecting a growth of 11.6%. The company's earnings per share (EPS) stood at $2.39, with a net margin of 17.3% and a return on equity of 14.7%. Investors are looking ahead to the next earnings report scheduled for July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Several insiders have been active recently. On May 28, 2026, Chairman, President & CEO Michael Mahoney sold 386,755 shares. Meanwhile, in a series of purchases on May 20, 2026, David Habiger acquired 2,250 shares at $55.92, Edward Ludwig bought 3,580 shares at $56.68, and Cheryl Pegus purchased 1,770 shares at $56.49. Earlier in May, Ellen Zane bought 3,800 shares.
Analysts Set New Price Targets
On June 24, 2026, Jefferies maintained its buy rating with a $67 price target. Other analysts also hold favorable views; BTIG reiterated a buy rating with a $65 target on June 16, 2026, while Truist Securities maintained a buy with a $64 target on June 4, 2026. The consensus among 29 analysts is a strong buy, with an average target price of $76.48.
About Boston Scientific
Boston Scientific Corporation is a global developer and manufacturer of medical devices used in various interventional medical specialties. Headquartered in Marlborough, Massachusetts, the company operates through its MedSurg and Cardiovascular segments. Led by CEO Michael F. Mahoney, it employs around 59,000 people and focuses on products for gastrointestinal, urological, and cardiovascular conditions, among others.
Bottom Line
Boston Scientific continues to attract attention with Jefferies reiterating its buy rating and a $67 price target. As a leading player in the medical devices industry, the company shows solid earnings growth and a strong market presence. Investors will be keenly watching the upcoming earnings report for further insights.
Get Boston Scientific Corporation alerts
New 13F filings, insider trades, and analyst moves on $BSX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.